Braunschweig, November 18, 2020 – CORAT Therapeutics CEO Dr. Andreas Herrmann today announced that the first major batch of its SARS-CoV-2 antibody COR-101 has been produced and is now available for clinical trials. COR-101 is a fully human antibody, which efficiently blocks the cell entry of SARS-CoV-2 thereby preventing the proliferation of corona viruses.
Read CORAT’s press release (English)
Read CORAT’s press release (German)
Dr. Thomas Schirrmann, CEO
Phone: +49-531 481170-0
CORAT Therapeutics GmbH
Dr. Andreas Herrmann, Managing Director
Phone: +49-152 2404 7488